The Rise of New Coronavirus Infection-(COVID-19): A Recent Update
The recent catastrophic outbreak of a novel coronavirus (COVID-19), currently renamed as COVID-19; recalled us the earlier memories created by the Severe Acute Respiratory Syndrome Human coronavirus (SARS-CoV) from nearly two decades ago. With the new advancements in earlier detection techniques for infections and better treatments; now we are better supported to deal this recent infestation of 2B coronavirus.
1.C Huang, Y Wang, X Li Clnical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020;20:30183–8.
2. Majumder, Maimuna and Mandl, Kenneth D., Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China (January 26, 2020). Available at SSRN: https://ssrn.com/abstract=3524675 or http://dx.doi.org/10.2139/ssrn.3524675
3. World Health Organization. Novel Coronavirus (2019-nCoV) situation reports Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
4. Centers for Disease Control and Prevention. Situation summary. Available at: https://www.cdc.gov/coronavirus/2019-ncov/ index.html.
5. Lippi, G. and Plebani, M., The novel coronavirus (2019-nCoV) outbreak: think the unthinkable and be prepared to face the challenge. Diagnosis.
6. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med 2019.
7. Hui, D.S., Madani, T.A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T.D., Memish, Z.A., Drosten, C., Zumla, A. and Petersen, E., 2020. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases, 91, p.264. [CrossRef]
8. Veljkovic, V., Vergara-Alert, J., Segalés, J. and Paessler, S., 2020. Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019- nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. F1000Research, 9(52), p.52. [CrossRef]
9. Paules, C.I., Marston, H.D. and Fauci, A.S., 2020. Coronavirus Infections-More Than Just the Common Cold. JAMA. [CrossRef]
10. Zhou P, Yang X-L, Wang X-G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in 2 humans and its potential bat origin. bioRxiv, January 23, 2020.
11. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217–e227. [CrossRef]
12. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med 2004;10:Suppl:S88–S97. [CrossRef]
13. Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 2004;363:1699–700. [CrossRef]
14. Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004;303:1666–9. [CrossRef]
15. Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol 2017;25:35– 48. [CrossRef]
16. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005;202:415–24. [CrossRef]
17. Sabir JS, Lam TT, Ahmed MM, et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 2016;351:81–4. [CrossRef]
18. Munster, V.J., Koopmans, M., van Doremalen, N., van Riel, D. and de Wit, E., 2020. A Novel Coronavirus Emerging in China— Key Questions for Impact Assessment. New England Journal of Medicine. [CrossRef]
19. MacIntyre CR. Wuhan novel coronavirus 2019nCoV – Update January 27th, 2020. Global Biosecurity 2019;1.
20. Linton, N.M., Kobayashi, T., Yang, Y., Hayashi, K., Akhmetzhanov, A.R., Jung, S.M., Yuan, B., Kinoshita, R. and Nishiura, H., 2020. Epidemiological characteristics of novel coronavirus infection: A statistical analysis of publicly available case data. medRxiv. [CrossRef]
21. Dunlop, C., Howe, A., Li, D. and Allen, L.N., 2020. The coronavirus outbreak: the central role of primary care in emergency preparedness and response. BJGP Open. [CrossRef]
22. Mahase E. Coronavirus: UK screens direct flights from Wuhan after US case. BMJ 2020;368:m265. [CrossRef]
23. Nishiura, H., Jung, S.M., Linton, N.M., Kinoshita, R., Yang, Y., Hayashi, K., Kobayashi, T., Yuan, B. and Akhmetzhanov, A.R., 2020. The extent of transmission of novel coronavirus in Wuhan, China, 2020. [CrossRef]
24. Available at :https://www.who.int/emergencies/diseases/ novel-coronavirus-2019/technical-guidance
25. Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X. and Zhang, Q., 2020. Coronavirus Infections and Immune Responses. Journal of Medical Virology. [CrossRef]
26. Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W. and Hao, P., 2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. SCIENCE CHINA Life Sciences. [CrossRef]
27. Paraskevis, D., Kostaki, E.G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G. and Tsiodras, S., 2020. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infection, Genetics and Evolution, p.104212. [CrossRef]
28. Benvenuto, D., Giovannetti, M., Ciccozzi, A., Spoto, S., Angeletti, S. and Ciccozzi, M., 2020. The 2019‐new coronavirus epidemic: evidence for virus evolution. Journal of Medical Virology.
29. Elfiky, A., 2020. Sofosbuvir Can Inhibit the Newly Emerged Coronavirus (2019-nCoV) in Wuhan, China. China (1/20/2020).
30. Tang, B., Wang, X., Li, Q., Bragazzi, N.L., Tang, S., Xiao, Y. and Wu, J., 2020. Estimation of the Transmission Risk of 2019-nCov and Its Implication for Public Health Interventions. Available at SSRN 3525558. [CrossRef]
31. Yang, Ming, Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection (January 29, 2020). Available at SSRN: https://ssrn.com/abstract=3527420 or http://dx.doi. org/10.2139/ssrn.3527420. [CrossRef]
32. Cookson BT, Brennan MA: Pro-inflammatory programmed cell death. Trends Microbiol 2001;9:113–4. [CrossRef]
33. Liu X, Zhang Z, Ruan J et al: Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 2016; 535:153–8. [CrossRef]
34. Chen IY, Moriyama M, Chang MF, Ichinohe T: Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome. Front Microbiol 2019;10. [CrossRef]
35. Jiang YT, Li JF, Teng Y et al: Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV. Viruses-Basel 2019;11. [CrossRef]
36. Fernandes-Alnemri T, Wu J, Yu JW et al: The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 2007; 14:1590–604. [CrossRef]
37. Wang S, Yuan YH, Chen NH, Wang HB: The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. Int Immunopharmacol 2019; 67458–64.
38. Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD: Caspase-1: the inflammasome and beyond. Innate Immun 2014;20:115–25. [CrossRef]
39. Perlman, S., 2020. Another decade, another coronavirus. DOI: 10.1056/NEJMe2001126 [CrossRef]
40. Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., Bleicker, T., Brünink, S., Schneider, J., Schmidt, M.L. and Mulders, D.G., 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, 25, p.2000045. [CrossRef]
41. Wu, J.T., Leung, K. and Leung, G.M., 2020. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. [CrossRef]
42. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y. and Yu, T., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet.
43. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N. and Bi, Y., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. [CrossRef]
44. Chan, J.F.W., Yuan, S., Kok, K.H., To, K.K.W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C.C.Y., Poon, R.W.S. and Tsoi, H.W., 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. [CrossRef]
45. Ji, J.S., 2020. Origins of MERS-CoV, and lessons for 2019-nCoV. The Lancet Planetary Health. DOI:https://doi.org/10.1016/ S2542–5196(20)30032–2. [CrossRef]
46. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Peter Richardson,Ivan Griffin,Catherine Tucker,Dan Smith,Olly Oechsle, Anne Phelan et al. Lancet , Published: February 04, 2020 DOI:https://doi.org/10.1016/ S0140–6736(20)30304–4. [CrossRef]
47. Heymann, D.L., 2020. Data sharing and outbreaks: best practice exemplified. The Lancet. DOI:https://doi.org/10.1016/S0140-6736(20)30184-7. [CrossRef]
48. Katterine Bonilla-Aldana, Keidenis Quintero-Rada, Juan PabloMontoya-Posada, SebastianRamírez, AlbertoPanizMondolfi, Ali Rabaan, Ranjit Sah, Alfonso J.RodríguezMorales, SARS-CoV, MERS-CoV and now the 2019-novel CoV: Have we investigated enough about coronaviruses? – A bibliometric analysis, Travel Medicine and Infectious Disease,101566, pre-proof. https://doi.org/10.1016/j. tmaid.2020.101566 [CrossRef]
49. The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: A data-driven correlational report, Shi Zhao, Zian Zhuang, Jinjun Ran, Jiaer Lin, GuangpuYang, LinYang, Daihai He, Travel Medicine and Infectious Disease,101568, pre-proof. https://doi.org/10.1016/j.tmaid.2020.101568 [CrossRef]
50. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI), Travel Medicine and Infectious Disease,101567, pre-proof. https://doi.org/10.1016/j. tmaid.2020.101567 [CrossRef]
51. Hoffmann, M., Kleine-Weber, H., Krueger, N., Mueller, M.A., Drosten, C. and Poehlmann, S., 2020. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. [CrossRef]
52. Carlos, W.G., Dela Cruz, C.S., Cao, B., Pasnick, S. and Jamil, S., 2020. Novel Wuhan (2019-nCoV) Coronavirus. American Journal of Respiratory and Critical Care Medicine, (ja). [CrossRef]
53. Riou, J. and Althaus, C.L., 2020. Pattern of early human-tohuman transmission of Wuhan 2019 novel coronavirus (2019- nCoV), December 2019 to January 2020. Eurosurveillance, 25(4), p. 2000058. [CrossRef]
54. Lu, H., 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends. DOI: 10.5582/ bst.2020.01020 [CrossRef]
55. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15:327–47. [CrossRef]
56. National Health Commission of the People's Republic of China. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 3). http://www.nhc.gov.cn/yzygj/ s7653p/202001/ f492c9153ea9437bb587ce2ffcbee1fa. shtml (accessed January 23, 2020).
57. Lei, C., Fu, W., Qian, K., Li, T., Zhang, S., Ding, M. and Hu, S., 2020. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bioRxiv.2020. doi: https://doi. org/10.1101/2020.02.01.929976 [CrossRef]
58. Wang, M., Cao, R., Zhang, L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res (2020). https://doi.org/10.1038/ s41422-020-0282-0. [CrossRef]
59. Zumla, A., Hui, D.S., Azhar, E.I., Memish, Z.A. and Maeurer, M., 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. The Lancet. [CrossRef]
60. Beigel JH Nam HH Adams PL et al. Advances in respiratory virus therapeutics-a meeting report from the 6th ISIRV antiviral group conference.Antiviral Res 2019;167:45–67. [CrossRef]
61. Zumla A Azhar EI Arabi Y et al. Host-directed therapies for improving poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections. Int J Infect Dis 2015;40:71–4. [CrossRef]
62. Stoermer, Martin (2020): Homology Models of the Papain-Like Protease PLpro from Coronavirus 2019-nCoV. ChemRxiv. Preprint. https://doi.org/10.26434/chemrxiv.11799705.v1
63. Ralph, R., Lew, J., Zeng, T., Francis, M., Xue, B., Roux, M., Ostadgavahi, A.T., Rubino, S., Dawe, N.J., Al-Ahdal, M.N. and Kelvin, D.J., 2020. 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness. J Infect Dev Ctries 2020;14:3–17. [CrossRef]
64. Li, G. and De Clercq, E., 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). [CrossRef]
65. De Clercq, E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem Asian J 2019;14:3962–8. [CrossRef]